Lorus Signs Agreement With Japan's Sumitomo and Koken

Lorus Therapeutics, a biopharmaceutical company specializing in the research, development and commercialization of pharmaceutical products and technologies for the management of cancer, announced that it has signed a collaboration agreement with Japan's leading pharmaceutical company, Sumitomo Pharmaceuticals and Koken. According to terms of the agreement, Lorus will provide Sumitomo proprietary antisense oligonucleotides complementary to Thioredoxin mRNA, specifically the lead drug candidate, GTI-2601.
CNW Telbec